Table 3.

Effects of in vivo treatment of K⁺-depleted rats for 10 days with ACTZ, DCP and BFT on lactate release from TA muscle

Muscle type and treatments	Lactate release (μg l−1 mg−1) 5 K+
TA of normokalemic rats (17)	15.31±4.1
TA of K+-depleted rats (3)	21.11±3.1*
TA of K+-depleted rats treated in vivo with ACTZ (3)	16.11±1.3**
TA of K+-depleted rats treated in vivo with BFT (3)	22.31±2.1
TA of K+-depleted rats treated in vivo with DCP (3)	23.18±3

Abbreviations: ACTZ, acetazolamide; BFT, bendroflumethiazide; DCP, dichlorphenamide; TA, tibialis anterioris.

All drugs were administered at a dose of 5.6 mg kg⁻¹ day⁻¹. Lactate release was evaluated in vitro under aerobic condition, at 35 °C, by spectrophotometric determination. Lactate release (μg l⁻¹ mg⁻¹) (5 K⁺) represents data from muscles incubated for 2 h in normal Ringer solution containing 5 mM K⁺. The numbers in the brackets represent the number of rats.

^*Significantly different from the data of normokalemic rats (P<0.05).

^**Significantly different from the data of untreated K⁺-depleted rats (P<0.05)